SGO Annual Meeting | Conferences

Previously Treated Patients With Vulvar Squamous Cell Carcinoma Have Durable Responses on Pembrolizumab

March 21, 2021

Data from the KEYNOTE-158 study, presented at the Society of Gynecological Oncology 2021 Virtual Annual Meeting on Women’s Cancer, showed durable responses in heavily pretreated patients with vulvar squamous cell carcinoma regardless of their PD-L1 status.

Apatinib/Doxorubicin Combination Improves PFS Over Single Agent in Ovarian Cancer

March 21, 2021

The combination of apatinib and pegylated liposomal doxorubicin improved the progression-free survival for patients with platinum-resistant or refractory ovarian cancer in comparison to doxorubicin alone, according to data from the phase 2 APPROVE trial.

PFS Benefit Sustained at 5-Year Follow-Up in SOLO-1 Trial of Maintenance Olaparib in Ovarian Cancer

March 21, 2021

After long-term follow-up, olaparib maintenance therapy demonstrated progression-free survival benefit in almost half of the patients with ovarian cancer compared with 21% for those who received placebo, including consistent benefit in high- and low-risk patients.

Niraparib Maintains PFS Improvement, But OS Data Are Limited in gBRCA+/- Ovarian Cancer

March 21, 2021

Niraparib administered as maintenance therapy showed clinical benefit lasting beyond first progression in patients with platinum-sensitive recurrent ovarian cancer with or without germline BRCA mutations, according to the final results of the ENGOT-OV16/NOVA study.